Venture Capital/Chips, aero, AI, robotics
Yali Capital logo

Yali Capital

Seed to Series A (deeptech) fund research profile

Yali Capital is a Bangalore-based early-stage deep-tech fund focused on technologies that can become globally relevant from India. Its stated sectors are semiconductors, aerospace and surveillance, AI, robotics, smart manufacturing and life sciences.

At a glance

Founded
2024
Footprint
Bengaluru
Stage
Seed to Series A (deeptech)

Research profile

Read the manager in sequence.

Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.

Investment lens

Yali Capital uses a seed to series a (deeptech) approach across Chips, aero, AI, robotics.

Current evidence

Yali’s current investment page lists seven deep-tech portfolio companies across six sectors; its public deal record includes PointAI invested in June 2025 and current positions such as 4baseCare, Perceptyne, C2i, LatentForce, Micropack, Ultraviolette and Deeplase.

Strategy

Seed to Series A (deeptech)

Sector focus

Chips, aero, AI, robotics

AIF structure context

Indian venture capital and angel-fund strategies are commonly structured as Category I AIFs. Verify the specific vehicle and registration before investing.

Current signal

Yali’s current investment page lists seven deep-tech portfolio companies across six sectors; its public deal record includes PointAI invested in June 2025 and current positions such as 4baseCare, Perceptyne, C2i, LatentForce, Micropack, Ultraviolette and Deeplase.

Investor questions

Yali Capital research questions

What is Yali Capital's investment strategy?

Yali Capital is covered in Rupeia's venture capital research universe. The current public record describes the strategy as Seed to Series A (deeptech), with a sector focus of Chips, aero, AI, robotics. The profile should be read with the linked source trail and Typical route: Category I AIF context.

What portfolio evidence is available for Yali Capital?

The profile displays only company or asset names attributable to Yali Capital in the reviewed public sources: 4baseCare, Perceptyne, C2i, LatentForce, Micropack, Ultraviolette, PointAI, Deeplase. It does not represent a complete current portfolio unless the manager has published one.

What is known about Yali Capital's performance or track record?

Yali’s own materials report a ₹893 crore corpus, seven active companies and one exit as of October 2026. The team’s prior record includes Cosmic Circuits, ideaForge and MTAR Technologies, but those prior outcomes should not be treated as Yali fund returns. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.

What are Yali Capital's fund size, fees and minimum investment?

Public fund size: Yali reports a ₹893 crore maiden deep-tech fund, above its original ₹500 crore target and ₹310 crore greenshoe option.. Public terms or access information: Early-stage deep-tech investing across six stated sectors; the GP publishes its stage and sector focus but not a standard cheque-size or reserve policy on the profile.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.

Who is on Yali Capital's investment team?

The current source record names Ganapathy Subramaniam, Mathew Cyriac. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.

What risks should be reviewed before investing with Yali Capital?

Review stage concentration, follow-on reserves, company failure rates, dilution, exit timing and the gap between paper valuations and realised distributions. The current open diligence point is: Deployment; team depth.

What is the latest public update on Yali Capital?

2025: Yali’s current investment page lists seven deep-tech portfolio companies across six sectors; its public deal record includes PointAI invested in June 2025 and current positions such as 4baseCare, Perceptyne, C2i, LatentForce, Micropack, Ultraviolette and Deeplase.

Next step

Need this manager reviewed against your mandate?

Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.

Request independent diligence →